title: Enzalutamide before chemotherapy prolongs survival.
abstract: In the phase III PREVAIL study, taking enzalutamide prior to chemotherapy improved survival and slowed progression of metastatic castration-resistant prostate cancer. The FDA is now considering an application to expand the drug's use to the pre-chemotherapy setting.
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001549:Benzamides; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide